Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends

Biomolecules. 2022 Dec 27;13(1):57. doi: 10.3390/biom13010057.

Abstract

Cucurbitacins constitute a group of cucumber-derived dietary lipids, highly oxidized tetracyclic triterpenoids, with potential medical uses. These compounds are known to interact with a variety of recognized cellular targets to impede the growth of cancer cells. Accumulating evidence has suggested that inhibition of tumor cell growth via induction of apoptosis, cell-cycle arrest, anti-metastasis and anti-angiogenesis are major promising chemo-preventive actions of cucurbitacins. Cucurbitacins may be a potential choice for investigations of synergism with other drugs to reverse cancer cells' treatment resistance. The detailed molecular mechanisms underlying these effects include interactions between cucurbitacins and numerous cellular targets (Bcl-2/Bax, caspases, STAT3, cyclins, NF-κB, COX-2, MMP-9, VEGF/R, etc.) as well as control of a variety of intracellular signal transduction pathways. The current study is focused on the efforts undertaken to find possible molecular targets for cucurbitacins in suppressing diverse malignant processes. The review is distinctive since it presents all potential molecular targets of cucurbitacins in cancer on one common podium.

Keywords: anti-angiogenic; anti-metastatic; anti-proliferation; apoptotic; cucurbitacins; synergism.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Apoptosis
  • Cucurbitacins / pharmacology
  • Cucurbitacins / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Neoplasms* / prevention & control
  • Signal Transduction
  • Triterpenes* / pharmacology
  • Triterpenes* / therapeutic use

Substances

  • Cucurbitacins
  • Antineoplastic Agents
  • Triterpenes

Grants and funding

A.P.K. was supported by the Singapore Ministry of Education, grant number (MOE-T2EP30120-0016). E.H.C.L. is supported by a PhD Scholarship from Yong Loo Lin School of Medicine, National University of Singapore. K.C.-Y.Y. is supported by a President’s Scholarship from National University of Singapore. S.M.C. is supported by an Industry PhD Scholarship from Singapore Economic Development Board.